Showing 4221-4230 of 7513 results for "".
- Researchers Identify Cause of Aggressive SCCs in Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/researchers-identify-cause-of-aggressive-sccs-in-recessive-dystrophic-epidermolysis-bullosa/2457636/Immune system-related enzymes contribute significantly to the development of aggressive and fatal squamous cell carcinomas early in the life of individuals with recessive dystrophic epidermolysis bullosa (RDEB), an international team of scientists led by researchers at the Sidney Kimmel Canc
- MC2 Therapeutics Reports Positive Topline Data for Investigational Topical for Psoriasishttps://practicaldermatology.com/news/mc2-therapeutics-reports-positive-topline-data-for-investigational-topical-for-psoriasis/2457641/MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics A/S achieved its primary and secondary endpoints, according to recently reported top-line data from the US Phase 3 study. Results of the
- Whale of a Tale: Shark Gets Botox Injectionshttps://practicaldermatology.com/news/whale-of-a-tale-shark-gets-botox-injections/2457642/It may sound fishy, but even sharks can benefit from Botox injections. Charles E. Crutchfield III, MD, and Crutchfield Dermatology in Eagan, MN recently assisted the veterinary staff at Minnesota Zoo in Apple Valley with a unique patient. Haps, a sand tiger shark, had
- "Phenomenal Gains" in Derm Device Market, Global Market Insights Predictshttps://practicaldermatology.com/news/phenomenal-gains-in-derm-device-market-global-market-insights-predicts/2457645/Dermatology devices market, an integral vertical of medical equipment space, of late, has been providing lucrative opportunities to the investors to exploit economies of scale. The claim is very well validated from the increasing attempts by the market giants to brainstorm innovative products tha
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://practicaldermatology.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2457649/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Neova Introduces Clinical Recovery Creamhttps://practicaldermatology.com/news/neova-introduces-clinical-recovery-cream/2457654/Neova SmartSkinCare is launching its Clinical Recovery range of products. The line of six new products is formulated to keep skin calm, soothed, hydrated, and protected following microdermabrasion, laser resurfacing, chemical peels,K and laser hair removal treatments for increased rates of healin
- Plastic Surgery Groups Issue Warning on the Risks of Brazilian Butt Liftshttps://practicaldermatology.com/news/plastic-surgery-groups-issue-warning-on-the-risks-of-brazilian-butt-lifts/2457659/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Castle Biosciences' DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence, Metastasishttps://practicaldermatology.com/news/castle-biosciences-decisiondx-melanoma-test-improved-ajcc-based-risk-prediction-for-melanoma-recurrence-metastasis/2457664/Castle Biosciences, Inc’s. DecisionDx®-Melanoma test improved risk prediction beyond that using American Joint Committee on Cancer (AJCC) based staging, according to a new study presented at the DERM2018 NP/PA CME Conference held in Las Veg
- IRB Approval Means BioPharmX To Move Ahead on Phase 2 Trial of BPX-04 for Rosaceahttps://practicaldermatology.com/news/irb-approval-means-biopharmx-to-move-ahead-on-phase-2-trial-of-bpx-04-for-rosacea/2457665/BioPharmX Corporation has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. Based on data from its open-label feasibility study which assessed tolera
- Dermatologist Named a Finalist for Inaugural FNIH Trailblazer Prize for Clinician-Scientistshttps://practicaldermatology.com/news/dermatologist-named-a-finalist-for-inaugural-fnih-trailblazer-prize-for-clinician-scientists/2457663/An oncodermatologist is in the running for the Foundation for the National Institutes of Health (FNIH) inaugural Trailblazer Prize for Clinician-Scientists. The three finalists are Daniel Bauer, MD, PhD, Harvard Medical School, Jaehyuk Choi, MD, PhD, Feinberg School of Medicine, North